AEYE Health

An FDA-cleared AI fundus-screening system that quickly diagnoses diabetic retinopathy.

4.3 Israel
Visit Website ↗

What is it: a medical-grade automated fundus-screening tool

AEYE Health is a US-FDA-cleared autonomous AI system designed for screening diabetic retinopathy. This technology's core advantage lies in its extremely high efficiency: with just one retinal image per eye, the system can immediately analyze and produce a diagnostic result. Unlike the traditional process requiring long interpretation by an ophthalmologist, AEYE Health, through deep-learning algorithms, can complete screening at the point of care, greatly shortening patients' report-waiting time and making medical-resource allocation more flexible and efficient.

What problem it solves: break the bottleneck of medical-resource distribution

Diabetic retinopathy is one of the leading causes of blindness, but many patients miss the golden treatment window due to inconvenient transport, difficult specialist appointments, or a tedious screening process. AEYE Health solves the pain point of primary-care clinics lacking ophthalmologists, letting general clinics or internists do high-quality fundus screening right in the consulting room.

This system is very suited to diabetes-care centers, primary-care clinics, and large medical institutions. By optimizing the screening process, it not only lowers the burden on the medical system but also improves patients' screening willingness and follow-up rate. For medical practitioners, this is a powerful tool for real-time decision aid, ensuring patients get necessary referral suggestions at the first moment and effectively preventing vision damage caused by diabetes — an indispensable smart solution in modern digital healthcare.

Key Features

  • Single-retinal-image analysis
  • Automated AI diagnosis technology
  • Real-time screening-report output
  • Fast point-of-care deployment
  • FDA-cleared medical-grade accuracy

Pros

  • Significantly shortens diagnosis time
  • Lowers the ophthalmology-screening barrier
  • Improves primary-care diagnostic efficiency

Cons

  • Limited to diabetic-retinopathy screening
  • Requires specific fundus-photography equipment

Use Cases

  • Primary-clinic diabetes follow-up
  • Remote-area telemedicine screening
  • Large-hospital fast triage

Editor's Note

This tool empowers primary care through AI, greatly optimizing the retinopathy-screening process for diabetes patients.

FAQ

How accurate is AEYE Health's diagnosis?

The system is US-FDA-cleared and has high clinical accuracy, effectively identifying signs of diabetic retinopathy.

How long does the screening process take?

The system is designed to run in real time at the point of care, needing just a single retinal image to produce a screening result in a short time.

Can this system replace an ophthalmologist?

The system is positioned as an aid screening tool aimed at helping medical staff quickly triage; the final diagnosis and treatment suggestions still need assessment by a professional ophthalmologist.

Related AI Tools

繁體中文版 →